(Total Views: 346)
Posted On: 10/24/2019 10:35:43 AM
Post# of 64
$HTBX News Article - Heat Biologics Announces a Poster Presentation of Updated Top Line Phase 2 Data of HS-110 plus Nivolumab after Checkpoint Inhibitor Treatment Failure in NSCLC Patients at the SITC 34th Annual Meeting https://marketwirenews.com/news-releases/heat...91183.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
